Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342849 · ClinicalTrials.gov registry record · Phase 3
Treatment of Lead-Exposed Children Trial
A Phase 3 study, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- Completed
- Registry status
- Phase 3
- Development phase
- 780
- Enrollment target
NCT00342849: Completed Phase 3 study, sponsored by National Institute of Environmental Health Sciences (NIEHS).
NCT00342849 is a Phase 3 study that has completed, run by National Institute of Environmental Health Sciences (NIEHS). The registered enrollment target is 780 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342849, a Phase 3 study, has completed, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 780 participants
- Enrollment target
Study Summary
The Treatment of Lead-Exposed Children (TLC) clinical trial compared the effect of lead chelation with succimer to placebo therapy. TLC was a randomized, double-blind, placebo-controlled clinical trial with sites in Cincinnati and Columbus, Ohio, Philadelphia, Pennsylvania, Baltimore, Maryland and Newark, New Jersey. The study was designed to test outcomes in IQ, neuropsychological function, behavior, physical growth and blood pressure three years after initiation of treatment. Enrollment was conducted between 1994 and 1997, with completion of the initial three-year follow-up in 2000.
Interventions
- DRUG Placebo
- DRUG Succimer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 1994-07-15 |
| Est. Completion | 2015-06-10 |
| Phase | Phase 3 |
What the finished NCT00342849 record still lists
NCT00342849 is an interventional study that assigns participants to a tested intervention. The registered 780 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00342849 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00342849 about?
NCT00342849 is a clinical study titled "Treatment of Lead-Exposed Children Trial". The Treatment of Lead-Exposed Children (TLC) clinical trial compared the effect of lead chelation with succimer to placebo therapy. TLC was a randomized, double-blind, placebo-controlled clinical trial with sites in Cincinnati and Columbus, Ohio, Philadelphia, Pennsylvania, Baltimore, Maryland and N...
What is the current status of trial NCT00342849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 780 participants. The study started on 1994-07-15. Estimated completion is 2015-06-10.
What interventions are being tested in trial NCT00342849?
The interventions under investigation include: Placebo (DRUG), Succimer (DRUG).
Who is sponsoring clinical trial NCT00342849?
This trial is sponsored by National Institute of Environmental Health Sciences (NIEHS), which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00342849's enrollment target sits among peer trials
780 434th of 2000 higher than 1,563 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI